Xspray Pharma Q2’22: End of Decade Vision Announced - Redeye

Redeye leaves its view on Xspray following friday's Q2 report, where it announced a vision of generating an excess of USD 250m in annual revenue with high margins at the end of the decade. In our view, the figures in the report were undramatic, as is often the case for a biotech company. Financing will be required before being cash flow positive.

Länk till analysen i sin helhet: https://www.redeye.se/research/850078/xspray-pharma-q222-end-of-decade-vision-announced?utm_source=finwire&utm_medium=RSS